Supplemental material
Drug Delivery
Volume 25, 2018 - Issue 1
Research Article
Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer
, , , , , , , , 
, , , , , , & show all
Tae Heung KangDepartment of Immunology School of Medicine, Konkuk University, Chungju, South Korea; http://orcid.org/0000-0002-9853-913XView further author information
http://orcid.org/0000-0002-9853-913XView further author information, , , , , , Hee Dong HanDepartment of Immunology School of Medicine, Konkuk University, Chungju, South Korea; Correspondence[email protected]
http://orcid.org/0000-0002-3300-5575View further author information
http://orcid.org/0000-0002-3300-5575View further author information & show allRelated Research Data
Assessing the responses of cellular proteins induced by hyaluronic acid-modified surfaces utilizing a mass spectrometry-based profiling system: Over-expression of CD36, CD44, CDK9, and PP2A
Source:
Royal Society of Chemistry (RSC)
Hyaluronic Acid Conjugated Magnetic Prussian Blue@Quantum Dot Nanoparticles for Cancer Theranostics
Source:
Ivyspring International Publisher
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Source:
Springer Science and Business Media LLC
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy
Source:
Springer Nature
Involvement of Endothelial Nitric Oxide in Sphingosine-1-Phosphate–Induced Angiogenesis
Source:
Ovid Technologies (Wolters Kluwer Health)
A prodrug strategy based on chitosan for efficient intracellular anticancer drug delivery
Source:
IOP Publishing
Tumorigenesis and the angiogenic switch
Source:
Springer Nature
RNAi-based nanomedicines for targeted personalized therapy
Source:
Elsevier BV
Natural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives
Source:
MDPI AG
Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery
Source:
American Chemical Society (ACS)
Tumor angiogenesis: molecular pathways and therapeutic targets
Source:
Springer Nature
In vivo activity of nuclease-resistant siRNAs
Source:
Cold Spring Harbor Laboratory
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Source:
Springer Nature
Regulation of Tumor Angiogenesis by EZH2
Source:
Elsevier BV
Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Source:
Taylor & Francis
Adverse effects of anticancer agents that target the VEGF pathway
Source:
Springer Nature
The role of tumor microenvironment in resistance to anti-angiogenic therapy
Source:
F1000 Research, Ltd.
Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity
Source:
Springer Science and Business Media LLC
siRNA-based approaches in cancer therapy.
Source:
Springer Science and Business Media LLC
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Source:
Elsevier BV
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Source:
American Association for Cancer Research (AACR)
Multilayered polyion complexes with dissolvable silica layer covered by controlling densities of cRGD-conjugated PEG chains for cancer-targeted siRNA delivery
Source:
Informa UK Limited
Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Source:
American Association for Cancer Research (AACR)
Nanoparticles for Cancer Targeting: Current and Future Directions
Source:
Bentham Science Publishers Ltd.
RNAi therapeutics: Principles, prospects and challenges
Source:
Elsevier BV
Chitosan/TPP and Chitosan/TPP-hyaluronic Acid Nanoparticles: Systematic Optimisation of the Preparative Process and Preliminary Biological Evaluation
Source:
Springer Science and Business Media LLC
Therapeutic Targeting of ATP7B in Ovarian Carcinoma
Source:
American Association for Cancer Research (AACR)
Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer
Source:
Taylor & Francis
Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Source:
Taylor & Francis Group
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo
Source:
Springer Nature
Linking provided by
